144 related articles for article (PubMed ID: 30158364)
1. Prognostic factors of daily blood examination for advanced melanoma patients treated with nivolumab.
Okuhira H; Yamamoto Y; Inaba Y; Kunimoto K; Mikita N; Ikeda T; Kaminaka C; Minami Y; Kanazawa N; Furukawa F; Jinnin M
Biosci Trends; 2018 Sep; 12(4):412-418. PubMed ID: 30158364
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy.
Nakamura Y; Kitano S; Takahashi A; Tsutsumida A; Namikawa K; Tanese K; Abe T; Funakoshi T; Yamamoto N; Amagai M; Yamazaki N
Oncotarget; 2016 Nov; 7(47):77404-77415. PubMed ID: 27764805
[TBL] [Abstract][Full Text] [Related]
3. Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
Tanizaki J; Haratani K; Hayashi H; Chiba Y; Nakamura Y; Yonesaka K; Kudo K; Kaneda H; Hasegawa Y; Tanaka K; Takeda M; Ito A; Nakagawa K
J Thorac Oncol; 2018 Jan; 13(1):97-105. PubMed ID: 29170120
[TBL] [Abstract][Full Text] [Related]
4. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients.
Khunger M; Patil PD; Khunger A; Li M; Hu B; Rakshit S; Basu A; Pennell N; Stevenson JP; Elson P; Panchabhai TS; Velcheti V
PLoS One; 2018; 13(10):e0197743. PubMed ID: 30359383
[TBL] [Abstract][Full Text] [Related]
5. The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study.
Karantanos T; Karanika S; Seth B; Gignac G
Clin Transl Oncol; 2019 Feb; 21(2):206-212. PubMed ID: 29948974
[TBL] [Abstract][Full Text] [Related]
6. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Fujimura T; Yamamoto Y; Hata H; Gosho M; Tanaka R; Yamaguchi K; Nonomura Y; Hirai I; Furudate S; Okuhira H; Imafuku K; Aoki M; Matsushita S
J Dermatol Sci; 2017 Nov; 88(2):225-231. PubMed ID: 28736218
[TBL] [Abstract][Full Text] [Related]
7. Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma.
Ishihara H; Tachibana H; Takagi T; Kondo T; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Target Oncol; 2019 Aug; 14(4):453-463. PubMed ID: 31359231
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
9. Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma.
Chasseuil E; Saint-Jean M; Chasseuil H; Peuvrel L; Quéreux G; Nguyen JM; Gaultier A; Varey E; Khammari A; Dréno B
Acta Derm Venereol; 2018 Apr; 98(4):406-410. PubMed ID: 29327065
[TBL] [Abstract][Full Text] [Related]
10. Serum 5-S-cysteinyl-dopa levels as a predictive marker for the efficacy of nivolumab in advanced malignant melanoma.
Umemura H; Kaji T; Tachibana K; Morizane S; Yamasaki O
Int J Biol Markers; 2019 Dec; 34(4):414-420. PubMed ID: 31648585
[TBL] [Abstract][Full Text] [Related]
11. Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Fujimura T; Yamamoto Y; Hata H; Tanaka R; Yamaguchi K; Nonomura Y; Hirai I; Furudate S; Okuhira H; Imafuku K; Aoki M; Matsushita S
Br J Dermatol; 2018 Jul; 179(1):213-215. PubMed ID: 29405254
[No Abstract] [Full Text] [Related]
12. Serum 5-S-cysteinyldopa behavior in the early phase of nivolumab treatment of 12 melanoma patients.
Omodaka T; Minagawa A; Uhara H; Wakamatsu K; Koizumi T; Yokokawa Y; Koga H; Okuyama R
J Dermatol; 2018 Nov; 45(11):1340-1344. PubMed ID: 30144152
[TBL] [Abstract][Full Text] [Related]
13. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
Martens A; Wistuba-Hamprecht K; Geukes Foppen M; Yuan J; Postow MA; Wong P; Romano E; Khammari A; Dreno B; Capone M; Ascierto PA; Di Giacomo AM; Maio M; Schilling B; Sucker A; Schadendorf D; Hassel JC; Eigentler TK; Martus P; Wolchok JD; Blank C; Pawelec G; Garbe C; Weide B
Clin Cancer Res; 2016 Jun; 22(12):2908-18. PubMed ID: 26787752
[TBL] [Abstract][Full Text] [Related]
14. Utility of Serum Inflammatory and Synovial Fluid Counts in the Diagnosis of Infection in Taper Corrosion of Dual Taper Modular Stems.
Kwon YM; Antoci V; Leone WA; Tsai TY; Dimitriou D; Liow MH
J Arthroplasty; 2016 Sep; 31(9):1997-2003. PubMed ID: 26994651
[TBL] [Abstract][Full Text] [Related]
15. Characterization of neutrophil-to-lymphocyte ratio as a measure of inflammation in rheumatoid arthritis.
Chandrashekara S; Mukhtar Ahmad M; Renuka P; Anupama KR; Renuka K
Int J Rheum Dis; 2017 Oct; 20(10):1457-1467. PubMed ID: 28952205
[TBL] [Abstract][Full Text] [Related]
16. Predicting marker for early progression in unresectable melanoma treated with nivolumab.
Kondo T; Nomura M; Otsuka A; Nonomura Y; Kaku Y; Matsumoto S; Muto M
Int J Clin Oncol; 2019 Mar; 24(3):323-327. PubMed ID: 30168088
[TBL] [Abstract][Full Text] [Related]
17. Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma.
Markovic O; Popovic L; Marisavljevic D; Jovanovic D; Filipovic B; Stanisavljevic D; Matovina-Brko G; Hajder J; Matkovic T; Živkovic R; Stanisavljevic N; Todorović M; Petrovic D; Mihaljevic B
Eur J Intern Med; 2014 Mar; 25(3):296-302. PubMed ID: 24565533
[TBL] [Abstract][Full Text] [Related]
18. Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shirotake S; Takamatsu K; Mizuno R; Kaneko GO; Nishimoto K; Oya M; Oyama M
Anticancer Res; 2019 Aug; 39(8):4371-4377. PubMed ID: 31366532
[TBL] [Abstract][Full Text] [Related]
19. Alterations of the neutrophil-lymphocyte ratio during the period of stable and acute exacerbation of chronic obstructive pulmonary disease patients.
Taylan M; Demir M; Kaya H; Selimoglu Sen H; Abakay O; Carkanat Aİ; Abakay A; Tanrikulu AC; Sezgi C
Clin Respir J; 2017 May; 11(3):311-317. PubMed ID: 26096858
[TBL] [Abstract][Full Text] [Related]
20. Procalcitonin better than C-reactive protein, erythrocyte sedimentation rate, and white blood cell count in predicting DNAemia in patients with sepsis.
Leli C; Cardaccia A; Ferranti M; Cesarini A; D'Alò F; Ferri C; Cenci E; Mencacci A
Scand J Infect Dis; 2014 Nov; 46(11):745-52. PubMed ID: 25195647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
